Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.34 |
| ▸ | FEN1 | P39748 | 8/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12823403 | 0.93 | ABCB1 (0.35) | FEN1ALOX5APSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12823908 | 0.91 | FFAR1 (0.40) | FEN1ALOX5APFFAR1FFAR4F10 | |
| SCHEMBL12823568 | 0.89 | FEN1 (0.36) | FEN1ALOX5APSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12822363 | 0.89 | FFAR1 (0.40) | FFAR1F10 | |
| SCHEMBL12822836 | 0.88 | FEN1 (0.35) | FEN1ALOX5APSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12821175 | 0.88 | FEN1 (0.35) | FEN1ALOX5APSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13586453 | 0.88 | FPR2 (0.32) | S1PR5FEN1ALOX5APSLC6A2SLC6A4 | |
| SCHEMBL12823842 | 0.87 | PPARD (0.40) | FFAR1FFAR4 | |
| SCHEMBL12822560 | 0.87 | ALOX5AP (0.38) | FEN1ALOX5AP | |
| SCHEMBL12823721 | 0.86 | FFAR4 (0.37) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | S1PR5 1548/4885FEN1 3340/4885ALOX5AP 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.